In another blockbuster cancer deal, Merck lays out up to $5.8B for half of Eisai's Lenvima
admin 8th March 2018 Uncategorised 0Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.
More: In another blockbuster cancer deal, Merck lays out up to .8B for half of Eisai's Lenvima
Source: fierce